Systemic lupus erythematosus - NYSORA

Explore NYSORA knowledge base for free:

Table of Contents

Contributors

Systemic lupus erythematosus

Systemic lupus erythematosus

Learning objectives

  • Describe systemic lupus erythematosus
  • Understand the potential complications associated with systemic lupus erythematosus
  • Anesthetic management of a patient with systemic lupus erythematosus

Definition and mechanisms

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disorder with a heterogeneous presentation and systemic involvement in which tissues and multiple organs are damaged by pathogenic autoantibodies and immune complexes
  • There are often periods of illness (flares) and periods of remission during which there are few symptoms

Signs and symptoms

  • Fatigue
  • Fever
  • Joint pain, stiffness, and swelling
  • Butterfly-shaped rash on the face that covers the cheeks and bridge of the nose or rashes elsewhere on the body
  • Skin lesions that appear or worsen with sun exposure
  • Fingers and toes that turn white or blue when exposed to cold or during stressful periods
  • Shortness of breath
  • Chest pain
  • Dry eyes
  • Photosensitivity
  • Headaches, confusion, and memory loss
  • Hair loss
  • Mouth ulcers
  • Swollen lymph nodes

Risk factors

  • Gender: Female > male 
  • Age: 15-45 years
  • Race: More common in African Americans, Hispanics, and Asian Americans

Causes

SLE is probably caused by a genetic susceptibility coupled with an environmental trigger, resulting in a defect in the immune system 

  • Genetics: Mutations in HLA-DR2/HLA-DR3 genes, complement genes, cytokine genes, etc.
  • Environmental: UV-light (UV-A, UV-B), viruses (e.g., EBV, CMV, retroviruses), drugs (e.g., minocycline, hydralazine, procainamide), hormones (e.g., estrogen, prolactin), heavy metals

Complications

  • Dermatologic: Malar rash, chronic discoid lesions
  • Brain and central nervous system: Headaches, dizziness, behavior changes, vision problems, strokes or seizures
  • Cardiovascular: Symptomatic pericarditis, pericardial tamponade, myocarditis, Libman-Sacks endocarditis, valvular dysfunction, Raynaud’s phenomenon
  • Pulmonary: Pleuritis, pneumonitis, diffuse alveolar hemorrhage, pulmonary arterial hypertension
  • Renal: Lupus nephritis, end-stage renal disease
  • Hematology: Anemia of chronic disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia
  • Gastrointestinal: Oral ulcers, Sjogren’s syndrome, dysphagia, acute abdominal pain, abnormal liver function tests, autoimmune hepatitis
  • Musculoskeletal: Arthritis, osteoporosis, fractures, asymptomatic atlantoaxial subluxation
  • Infection: SLE and treatment can weaken the immune system
  • Pregnancy complications: Increased risk of miscarriage, high blood pressure during pregnancy, and preterm birth

Pathophysiology

systemic lupus erythematosus, SLE, genetic, environment, autoimmune disease, immune system, dendritic cells, B-cells, T-cells, pathophysiology, auto-antibodies, auto-reactive T-cells, immune complexes, cytokines

Treatment

DrugIndicationAnesthetic implications
Aspirin/NSAIDs (ibuprofen, naproxen sodium)Antiphospholipid syndrome
SLE arthritis
Peptic ulceration
Platelet inhibition
Renal impairment
Fluid retention/electrolyte disturbance
Hepatic dysfunction
Bronchospasm
Antimalarial drugs (hydroxychloroquine)Cutaneous SLE
Pleuritis/pericarditis
Arthritis
Reduced renal flares
Retinotoxicity
Neuromyotoxicity
Cardiotoxicity
Corticosteroids (prednisone, methylprednisone, topical preparation)Cutaneous SLE
Nephritis
Pleuritis/pericarditis
Diffuse alveolar hemorrhage
Neuropsychiatric SLE
Mesenteric vasculitis
SLE pancreatitis
Hyperglycemia
Hypercholesterolemia
Hypertension
Osteoporosis
Immunosuppressants
CyclophosphamideNephritis
Neuropsychiatric SLE
Myelosuppression
Pseudocholinesterase inhibition
Cardiotoxicity
Leucopenia
Hemorrhagic cystitis
AzathioprineArthritisMyelosuppression
Hepatotoxicity
MethotrexateArthritis
Cutaneous SLE
Myelosuppression
Hepatic fibrosis/cirrhosis
Pulmonary infiltrates/fibrosis
Mycophenolate mofetilNephritis
Hemolytic anemia, thrombocytopenia
GI upset
Pancytopenia

Management

Preoperative management

  • History: Review disease activity index, accrued organ damage, and drug history
  • Examination: Thorough examination of cardiovascular, respiratory, and neurological systems, including testing for atlantoaxial subluxation symptoms and signs
  • Full blood count: Test for anemia, thrombocytopenia, and leucopenia; consider further testing for hemolysis if anemia is present
  • Serum electrolytes, creatinine, urea: Any abnormality requires further investigation for lupus nephritis
  • Liver function tests: Abnormalities should prompt review for autoimmune or drug hepatotoxicity
  • Coagulation studies: Elevated aPTT requires investigation for the presence of lupus anticoagulant
  • Anti-dsDNA, complement levels: May reflect lupus activity after comparison with previous baseline measurements
  • Urinalysis: Proteinuria, red cells, white cells, and cellular casts may indicate clinically silent disease and prompt further investigation
  • ECG: Silent ischemia, myocarditis, pericarditis, and conduction abnormalities may be identified
  • Chest radiograph: Pleural effusion, interstitial pneumonitis, pericardial effusion, or subglottic stenosis may be seen

Intraoperative management

  • 5-lead ECG: Accelerated coronary artery disease, conduction abnormalities
  • Intra-arterial blood pressure monitoring: Case-dependent, consider in the presence of myocarditis, conduction abnormalities, valvular abnormalities, or autonomic dysfunction
  • Laryngeal mask airway if appropriate: Minimize airway manipulation due to the risk of inflammation and post-extubation airway edema
  • Difficult airway precautions with immediate access to smaller-size endotracheal tubes: Vocal cord paralysis, subglottic stenosis, or laryngeal edema may make intubation difficult
  • Standard antibiotic prophylaxis: Innate susceptibility to infection and immunosuppressive therapy predispose to infection risk
  • Caution with muscle relaxants: Azathioprine and cyclophosphamide may interact with muscle relaxants
  • Renal protective strategies: Maintain urine output, avoid hypoperfusion and hypotensive states, and use nephrotoxic drugs cautiously due to the possibility of subclinical lupus nephritis
  • Careful patient positioning: Predisposition to peripheral neuropathies and osteoporosis
  • Antithrombotic prophylaxis: Institute mechanical and pharmacological measures early, especially in the presence of antiphospholipid antibodies
  • Eye protection and artificial tears/lubrication: Sjogren’s syndrome may predispose to corneal abrasions despite adequate eye taping
  • Temperature monitoring: Hypothermic state may induce vasospasm in patients with Raynaud’s phenomenon
  • Pain management: Consider side effects of systemic analgesics; regional techniques may be helpful if neuropathies, myelitis, and coagulopathies are excluded
  • Corticosteroid cover: Adrenal suppression may have resulted from long-term corticosteroid therapy with the need for a “stress dose” perioperatively

Postoperative management

  • Pain management: Minimize systemic side effects

Keep in mind

  • A thorough preanesthetic evaluation is mandatory for safe anesthesia
  • The anesthetic plan must be individualized based on the degree of involvement of various systems, current medications, and laboratory results

Suggested reading

  • Erez BM. Systemic Lupus Erythematosus: A Review for Anesthesiologists. Anesthesia & Analgesia. 2010;111(3):665-676.

We would love to hear from you. If you should detect any errors, email us customerservice@nysora.com

Upcoming Events View All